What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...
Verywell Health on MSN14h
Another Study Links Ozempic to a Rare Eye Condition That Can Cause Vision LossA new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...
Seeking Alpha on MSN7h
Novo Nordisk seeks to block compounded VictozaNovo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies to produce Victoza, also known as liraglutide, following a proposal by the ...
Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...
Two new studies suggest that the diabetes medication Ozempic may double the risk of a rare but serious condition that damages ...
17don MSN
A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, ...
The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes ...
The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...
Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...
Shares in Ozempic maker Novo Nordisk crashed, after an experimental anti-obesity shot fell short of expectations. The shares ...
Novo Nordisk's (NVO) GLP weight-loss drug Ozempic has reportedly been linked to a rare form of vision loss, known as non-arteritic anterior ischemic optic neuropathy (NAION). The study ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback